NCT02259114View on ClinicalTrials.gov

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 23, 2014

Primary Completion Date

March 3, 2017

Study Completion Date

March 3, 2017

Conditions
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS MutationCastrate-resistant Prostate CancerCRPCPancreatic Ductal Adenocarcinoma
Interventions
DRUG

Birabresib

Birabresib 10, 20 and/or 40 mg oral capsules

All Listed Sponsors
lead

Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | Biotech Hunter | Biotech Hunter